Lak Shin Jeong
Inventor
Stats
- 5 US patents issued
- 10 US Applications filed
- most recent filing
This is official USPTO record data
Details
- 5 US Patents Issued
- 10 US Applications Filed
- 17 Total Citation Count
- May 31, 2022 Most Recent Filing
- Oct 24, 2003 Earliest Filing
Work History
Patent Owner | Applications Filed | Year |
---|---|---|
FM THERAPEUTICS CO., LTD. | 2
| 2007
|
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2
2 | 2003
2007 |
EWHA UNIVERSITY - INDUSTRY COLABORATION FOUNDATION | 1
| 2013
|
REXAHN PHARMACEUTICALS, INC. | 1
| 2005
|
Ewha University—Industry Collaboration Foundation | 1
1 | 2012
2013 |
EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION | 1
2 2 1 | 2010
2012 2013 2014 |
SNU R&DB FOUNDATION | 1
| 2015
|
EWHA WOMANS UNIVERSITY | 2
| 2003
|
INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY | 1
| 2015
|
Inventor Addresses
Address | Duration |
---|---|
Seoul, KR | Nov 17, 05 - Sep 12, 24 |
Technology Profile
Technology | Matters | |
---|---|---|
A01N: | PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF | 2 |
A61K: | PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES | 7 |
A61P: | THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS | 2 |
Patents / Publication
Patents / Publication # | Year of Publication / Issued | Title | Citations |
---|---|---|---|
2024/0300,991 | 2024 | NUCLEOSIDE DERIVATIVE HAVING MULTI-TARGET KINASE INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING CANCER COMPRISING SAME | 0 |
11510899 | 2022 | RTX toxin production inhibitor and composition for treating symptom of vibrio infection by using same | 0 |
2020/0237,718 | 2020 | RTX TOXIN PRODUCTION INHIBITOR AND COMPOSITION FOR TREATING SYMPTOM OF VIBRIO INFECTION BY USING SAME | 0 |
10100011 | 2018 | Pentadienoyl piperidine derivative and use thereof | 0 |
2017/0320,825 | 2017 | NOVEL PENTADIENOYL PIPERIDINE DERIVATIVE AND USE THEREOF | 0 |
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level.
>
Upgrade to our Level for up to -1 portfolios!.